Evidence map›Paper›PMID 33609479›Full record

ReviewThe Lancet. Neurology2021

New insights into atypical Alzheimer's disease in the era of biomarkers.

Jonathan Graff-Radford, Keir X X Yong, Liana G Apostolova, Femke H Bouwman, Maria Carrillo, Bradford C Dickerson, Gil D Rabinovici, Jonathan M Schott, David T Jones, Melissa E Murray

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 410 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
410citing papers in PubMed, 8 pooled it
45.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

410 citing papers in PubMed, 8 syntheses or guidelines pooled it, 627 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Oxidative stress in neurodegeneration: from a simple insult to a dynamic regulator.Redox report : communications in free radical research · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Operationalizing Alzheimer's disease trials in the era of targeted therapies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  20. Article

350 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, USA. Electronic address: graff-radford.jonathan@mayo.edu.
Keir X X YongDementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Liana G ApostolovaDepartment of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.
Femke H BouwmanAlzheimer Center Amsterdam, Department of Neurology, Amsterdam University Medical Center, Amsterdam, Netherlands.
Maria CarrilloAlzheimer's Association, Chicago, IL, USA.
Bradford C DickersonDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Gil D RabinoviciDepartment of Neurology, Radiology, and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Jonathan M SchottDementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
David T JonesDepartment of Neurology, Mayo Clinic, Rochester, MN, USA; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Mayo Clinic in Arizona · USUniversity College London · GBAlzheimer's Association · USHarvard University · USIndiana University – Purdue University Indianapolis · USMayo Clinic in Florida · USUniversity of California, San Francisco · US

Funding

Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
Early Onset Alzheimer's Disease ConsortiumR56AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2017 to 2017
$7.7M
Clinicopathologic and Neuroimaging Differences in Alzheimer's Disease VariantsR01AG054449 · NIA · MAYO CLINIC JACKSONVILLE · PI MURRAY, MELISSA ERIN · 2017 to 2021
$3.9M
NIA NIH HHS P30 AG062421NIA NIH HHS R01 AG054449NIA NIH HHS R56 AG057195NIA NIH HHS U01 AG057195
6 · The paper itself

Abstract

Most patients with Alzheimer's disease present with amnestic problems; however, a substantial proportion, over-represented in young-onset cases, have atypical phenotypes including predominant visual, language, executive, behavioural, or motor dysfunction. In the past, these individuals often received a late diagnosis; however, availability of CSF and PET biomarkers of Alzheimer's disease pathologies and incorporation of atypical forms of Alzheimer's disease into new diagnostic criteria increasingly allows them to be more confidently diagnosed early in their illness. This early diagnosis in turn allows patients to be offered tailored information, appropriate care and support, and individualised treatment plans. These advances will provide improved access to clinical trials, which often exclude atypical phenotypes. Research into atypical Alzheimer's disease has revealed previously unrecognised neuropathological heterogeneity across the Alzheimer's disease spectrum. Neuroimaging, genetic, biomarker, and basic science studies are providing key insights into the factors that might drive selective vulnerability of differing brain networks, with potential mechanistic implications for understanding typical late-onset Alzheimer's disease.

Indexed as

BiomarkersAgedAged, 80 and overAge of OnsetAlzheimer DiseaseFemaleHumansMaleMiddle AgedNeuroimagingBiomarkers

Identifiers

PMID33609479
PMCPMC8056394
OpenAlexW3131646863

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.